J Adolesc Health. 2018 Oct;63(4):513-516. doi: 10.1016/j.jadohealth.2018.07.021.
Pre-exposure prophylaxis (PrEP) is a biomedical prevention intervention that has demonstrated high efficacy in reducing human immunodeficiency virus (HIV) transmission. While an increasing number of jurisdictions have endorsed the use of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) for PrEP, access to PrEP varies widely. Adolescents and young adults (AYAs), especially those at high risk of HIV acquisition, such as young gay, bisexual, and other men having sex with men (YGBMSM) and individuals living in countries where HIV is endemic, face multiple barriers that limit their access to PrEP. This position paper provides context and recommendations for the promotion and use of PrEP among AYAs.
暴露前预防（PrEP）是一种具有高度有效性的医学专业学术文献生物医学预防干预措施，可以降低人类免疫缺陷病毒（HIV）的传播。虽然越来越多的司法管辖区认可将恩曲他滨/替诺福韦二吡呋酯（FTC/TDF）用于 PrEP，但 PrEP 的可及性差异很大。青少年和年轻成年人（AYAs），尤其是那些感染 HIV 风险较高的人群，如年轻的男同性恋、双性恋和其他男男性行为者（YGBMSM）以及生活在 HIV 流行的国家的个人，面临着多种限制他们获得 PrEP 的障碍。本立场文件为促进和使用 PrEP 提供了背景和建议。
